The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025 - DXCM

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, the G6 and G7, which were not authorized by the FDA and posed health risks to users [1]. Group 1: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring devices, which rendered them less reliable than previous versions [1]. - It is alleged that the enhancements to the G7's reliability, accuracy, and functionality were overstated, and the company downplayed the severity of the issues related to the devices [1]. - The complaint suggests that these actions increased the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is December 26, 2025, and there is no cost to participate in the case [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2].